Safety of TeaCrine®, a non-habituating, naturally-occurring purine alkaloid over eight weeks of continuous use

Table 1 Macronutrient intakes

Variable	T1	T2	T3	Time*group	Timegroupgender
kcal/d
PLA	2054 ± 700	2132 ± 822	2128 ± 778	Time p = 0.11	GTGe p = 0.17
LD	2469 ± 727	2450 ± 957	2155 ± 563	G*T p = 0.39
HD	2478 ± 1252	2395 ± 1139	2031 ± 763	G*T p = 0.39
Fat g/d
PLA	85 ± 30	83 ± 32	92 ± 50	Time p = 0.89	GTGe p = 0.41
LD	101 ± 47	105 ± 50	104 ± 30	G*T p = 0.42
HD	100 ± 60	94 ± 55^a	83 ± 35^a	G*T p = 0.42
Protein g/d
PLA	106 ± 32	94 ± 28	96 ± 36	Time p = 0.04	GTGe p = 0.40
LD	108 ± 62	101 ± 46	90 ± 34	G*T p = 0.48
HD	110 ± 69	108 ± 57	83 ± 48	G*T p = 0.48
Carb g/d
PLA	223 ± 109	320 ± 297	234 ± 91	Time p = 0.23	GTGe p = 0.37
LD	284 ± 102	284 ± 119	266 ± 89	G*T p = 0.52
HD	282 ± 127	280 ± 148	235 ± 102	G*T p = 0.52

Abbreviations: PLA Placebo, LD Theacrine Low Dose, HD Theacrine High Dose, G Group, T Time, Ge Gender
Superscript letters, different letters are significantly different at a given time point (p < 0.05). Items in bold indicate a significant effect (p < 0.05) was observed